SEPTIN9 methylation in ctDNA predicts MRD in colorectal cancer patients post-surgery
The study evaluates SEPTIN9 methylation status in ctDNA as a biomarker for minimal residual disease in colorectal cancer.
Phase III
colorectal cancer therapies
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The identification of SEPTIN9 methylation as a predictive biomarker for minimal residual disease in colorectal cancer could significantly influence treatment protocols and patient management. Pharma companies should consider the implications for their clinical strategies in CRC therapies, particularly regarding MRD monitoring.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor further validation studies and potential clinical adoption of SEPTIN9 as a standard biomarker for MRD in CRC.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.